Discuss how to develop a structured approach for administering checkpoint inhibitors in urologic practice as part of a structured program.
Manage adverse events from checkpoint inhibitors
Identify practice implications of implementing a checkpoint inhibitor program
Checkpoint inhibitors (CPIs) are increasingly being utilized in the treatment of urinary tract cancers, with several approvals in metastatic and now localized disease states. Urologists are embracing these therapies and contemplating bringing them into their own clinics and practices. Centralizing patients’ oncologic care, simplifying combination treatment strategies, and providing value-based and efficient cancer care are major reasons to begin administering CPIs for urologists. This course will discuss and provide a structured approach to incorporating checkpoint inhibitors in a busy urologic practice. The course is divided in 3 major sections: indications and introduction; building an immuno-oncology (IO) program; and clinical monitoring/side effect management. Attendees will gain a overall understanding of the clinical facets of caring for patients on immunotherapy as well as infrastructure and personnel requirements for program support. Specific attention will be given to logistical issues such as patient navigation and education, infusion workflow, and financial/economic practice considerations. A case-based section on adverse effect management will be presented with key take home messages to improve urologist comfort surrounding this issue.